Heart rate regularisation in patients with permanent atrial fibrillation implanted with a VVI(R) pacemaker

Mazzocca, G.; Giovannini, Tiziana; Frascarelli, Fabio; Fabiani, Andrea; Burali, Antonio; Giappichini, Giampiero; Bidi, Giuseppe; Bernabò, Daniele; Manfredini, E.; Corbucci, Giorgio

doi:10.1016/j.eupc.2004.02.002

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our view, VVIR is not the optimal programming mode to drive the ventricular pacing rate and achieve regularization in patients with AF and marked sympathetic activation, as rate response calculated by sensors would not correlate with the elevated ventricular rates found in these patients both at rest and moderate exercise. A better approach would be to compare VRR with fixed rate VVI pacing at “the best” fixed rate that could achieve the highest degree of regularization, 30 even if this value is often difficult to obtain in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Rate Control and Regularization Through Pacing in Patients With Chronic Atrial Fibrillation and Preserved Ventricular Function: The VRR Study

Ciaramitaro

Sgarito

Solimene

et al. 2006

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…patients both at rest and moderate exercise. A better approach would be to compare VRR with fixed rate VVI pacing at "the best" fixed rate that could achieve the highest degree of regularization, 30 even if this value is often difficult to obtain in clinical practice.…”

Section: Rate Regularization In Atrial Fibrillationmentioning

confidence: 99%

Role of Rate Control and Regularization Through Pacing in Patients With Chronic Atrial Fibrillation and Preserved Ventricular Function: The VRR Study

Ciaramitaro

Sgarito

Solimene

et al. 2006

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

Reversal Agents in the Era of NOACs: 2017 Update

Chen

et al. 2017

Journal of Atrial Fibrillation

View full text Add to dashboard Cite

The incidence and prevalence of atrial fibrillation (AF) is expected to more than double between 2010 and 2030. Accordingly, the use of non-vitamin K oral anticoagulant (NOAC) agents for thromboembolic stroke prevention is anticipated to increase. The development of effective and safe antidotes is needed to address the unmet need for rapid anticoagulation reversal. The immediate role for these novel antidotes is for reversal of NOAC activity in life threatening bleeding and urgent surgical intervention. In addition, reversal agents may play an important role in simplifying bridging protocols in the peri-procedural period for catheter ablation of AF and elective surgery. Currently, novel reversal agents are either decoy drug receptors or small molecule non-specific anticoagulant activity inhibitors. These agents are at various stages of FDA investigation and approval, with emerging prospective data for safety and efficacy. The purpose of this review is to outline the currently developed NOAC molecular antagonists, their potential clinical roles and future directions.

show abstract

Heart rate regularisation in patients with permanent atrial fibrillation implanted with a VVI(R) pacemaker

Abstract: The RCP estimates, during pacing, what the spontaneous MHR would be. Ventricular stimulation at the RCP causes a high P%, stabilising cardiac cycles with a modest increase in HR.

Cited by 2 publications

References 18 publications

Role of Rate Control and Regularization Through Pacing in Patients With Chronic Atrial Fibrillation and Preserved Ventricular Function: The VRR Study

Role of Rate Control and Regularization Through Pacing in Patients With Chronic Atrial Fibrillation and Preserved Ventricular Function: The VRR Study

Reversal Agents in the Era of NOACs: 2017 Update

Contact Info

Product

Resources

About